RegentAtlantic Capital’s NovoCure NVCR Stock Holding History

RegentAtlantic Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$229K	Hold	3,015	–	–	0.01%	610
2022 Q2	$210K	Hold	3,015	–	–	0.01%	631
2022 Q1	$250K	Hold	3,015	–	–	0.01%	612
2021 Q4	$226K	Hold	3,015	–	–	0.01%	640
2021 Q3	$350K	Sell	3,015 -3	-0.1%	-$454	0.01%	515
2021 Q2	$669K	Hold	3,018	–	–	0.02%	357
2021 Q1	$399K	Sell	3,018 -157	-5%	-$24.8K	0.01%	424
2020 Q4	$549K	Sell	3,175 -1,040	-25%	-$142K	0.02%	326
2020 Q3	$469K	Buy	4,215 +88	+2%	+$7.04K	0.02%	330
2020 Q2	$245K	Buy	4,127 +15	+0.4%	+$987	0.01%	426
2020 Q1	$277K	Sell	4,112 -888	-18%	-$70.2K	0.02%	341
2019 Q4	$421K	Hold	5,000	–	–	0.03%	335
2019 Q3	$374K	Hold	5,000	–	–	0.02%	344
2019 Q2	$316K	Sell	5,000 -112	-2%	-$5.67K	0.02%	355
2019 Q1	$246K	Sell	5,112 -2,069	-29%	-$99.6K	0.02%	389
2018 Q4	$240K	Buy	7,181 +112	+2%	+$4.09K	0.02%	366
2018 Q3	$370K	Hold	7,069	–	–	0.03%	324
2018 Q2	$221K	Buy	+7,069	New	+$197K	0.02%	380
2018 Q1	–	Sell	-19,294	Closed	-$390K	–	420
2017 Q4	$390K	Hold	19,294	–	–	0.03%	320
2017 Q3	$383K	Hold	19,294	–	–	0.03%	311
2017 Q2	$334K	Hold	19,294	–	–	0.03%	313
2017 Q1	$156K	Hold	19,294	–	–	0.01%	390
2016 Q4	$151K	Hold	19,294	–	–	0.01%	381
2016 Q3	$165K	Hold	19,294	–	–	0.02%	375
2016 Q2	$225K	Buy	+19,294	New	+$242K	0.02%	354

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RegentAtlantic Capital's NVCR Position: Q3 2022 in Review

RegentAtlantic Capital held its NovoCure (NVCR) position steady in Q3 2022 at 3,015 shares worth $229K. The position accounts for 0.01% of the portfolio, ranked #610.

RegentAtlantic Capital first reported a position in NVCR in Q2 2016 and has held it in 25 quarters since. The position peaked at $669K in Q2 2021. 303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

RegentAtlantic Capital held 3,015 shares of NovoCure worth $229K as of Q3 2022.
RegentAtlantic Capital left its NovoCure share count unchanged in Q3 2022.
NovoCure made up 0.01% of RegentAtlantic Capital's portfolio in Q3 2022, its #610 holding.
RegentAtlantic Capital first reported a position in NovoCure in Q2 2016 and has held it in 25 quarters since.
RegentAtlantic Capital's NovoCure position peaked at $669K in Q2 2021.
303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.